2.50
Hdl Handle:
http://hdl.handle.net/2336/15514
Title:
HPV genotypes in CIN 2-3 lesions and cervical cancer: a population-based study.
Authors:
Sigurdsson, Kristjan; Taddeo, Frank J; Benediktsdottir, Kristrun R; Olafsdottir, Kristrun; Sigvaldason, Helgi; Oddsson, Kristjan; Rafnar, Thorunn
Citation:
Int. J. Cancer 2007, 121(12):2682-7
Issue Date:
15-Dec-2007
Abstract:
The distribution of human papillomavirus (HPV) varies between countries and continents leading to different effectiveness of upcoming prophylactic HPV vaccines. This study analyses the HPV distribution in CIN 2-3, recurrent CIN 2-3 and cervical cancer in Iceland. About 80% of incident cases with CIN 2-3 lesions in 1990 and 1999, 99% of cancer cases in 1990-1994 and 1999-2003, and cases with recurrent CIN 2-3 after conization in 1990 were tested with PCR analysis for the presence of 12 oncogenic HPV types. About 95% of the CIN 2-3 and 92% of the cancer cases tested positive for the included HPV types. HPV 16 was the most frequent type followed by HPV 33, 31, 52, 35, 18, 58, 56, 39, 45, 59 in CIN 2-3 and by HPV 18, 33 45, 31, 39, 52, 35, 51, 56 in cancer. HPV 16 and 18 were associated with a significantly increased cancer risk and HPV 52 and 31 with decreased cancer risk compared to the risk of CIN 3. The HPV distribution differed between histological cancer types, stages and age groups. The number of HPV types was not a significant predictor of cancer. Oncogenic HPV types were found in all persistent or recurrent CIN 2-3 disease after conization. Vaccination against HPV 16/18 is estimated to achieve a minimum 40% reduced rate of CIN 2-3 and a minimum 60% reduced cancer rate. This rate could, however, be increased to 95% and 92% respectively by including all the 12 HPV types tested for in this study.
Description:
To access publisher full text version of this article. Please click on the hyperlink in Additional Links field
Additional Links:
http://dx.doi.org/10.1002/ijc.23034

Full metadata record

DC FieldValue Language
dc.contributor.authorSigurdsson, Kristjan-
dc.contributor.authorTaddeo, Frank J-
dc.contributor.authorBenediktsdottir, Kristrun R-
dc.contributor.authorOlafsdottir, Kristrun-
dc.contributor.authorSigvaldason, Helgi-
dc.contributor.authorOddsson, Kristjan-
dc.contributor.authorRafnar, Thorunn-
dc.date.accessioned2007-12-28T14:38:54Z-
dc.date.available2007-12-28T14:38:54Z-
dc.date.issued2007-12-15-
dc.date.submitted2007-12-28-
dc.identifier.citationInt. J. Cancer 2007, 121(12):2682-7en
dc.identifier.issn0020-7136-
dc.identifier.pmid17724723-
dc.identifier.doi10.1002/ijc.23034-
dc.identifier.urihttp://hdl.handle.net/2336/15514-
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links fielden
dc.description.abstractThe distribution of human papillomavirus (HPV) varies between countries and continents leading to different effectiveness of upcoming prophylactic HPV vaccines. This study analyses the HPV distribution in CIN 2-3, recurrent CIN 2-3 and cervical cancer in Iceland. About 80% of incident cases with CIN 2-3 lesions in 1990 and 1999, 99% of cancer cases in 1990-1994 and 1999-2003, and cases with recurrent CIN 2-3 after conization in 1990 were tested with PCR analysis for the presence of 12 oncogenic HPV types. About 95% of the CIN 2-3 and 92% of the cancer cases tested positive for the included HPV types. HPV 16 was the most frequent type followed by HPV 33, 31, 52, 35, 18, 58, 56, 39, 45, 59 in CIN 2-3 and by HPV 18, 33 45, 31, 39, 52, 35, 51, 56 in cancer. HPV 16 and 18 were associated with a significantly increased cancer risk and HPV 52 and 31 with decreased cancer risk compared to the risk of CIN 3. The HPV distribution differed between histological cancer types, stages and age groups. The number of HPV types was not a significant predictor of cancer. Oncogenic HPV types were found in all persistent or recurrent CIN 2-3 disease after conization. Vaccination against HPV 16/18 is estimated to achieve a minimum 40% reduced rate of CIN 2-3 and a minimum 60% reduced cancer rate. This rate could, however, be increased to 95% and 92% respectively by including all the 12 HPV types tested for in this study.en
dc.language.isoenen
dc.relation.urlhttp://dx.doi.org/10.1002/ijc.23034en
dc.subject.meshAdulten
dc.subject.meshAgeden
dc.subject.meshCervical Intraepithelial Neoplasiaen
dc.subject.meshDNA, Viralen
dc.subject.meshFemaleen
dc.subject.meshGenotypeen
dc.subject.meshHuman papillomavirus 16en
dc.subject.meshHumansen
dc.subject.meshIcelanden
dc.subject.meshLogistic Modelsen
dc.subject.meshMass Screeningen
dc.subject.meshMiddle Ageden
dc.subject.meshNeoplasm Recurrence, Localen
dc.subject.meshOdds Ratioen
dc.subject.meshPapillomaviridaeen
dc.subject.meshPapillomavirus Infectionsen
dc.subject.meshPredictive Value of Testsen
dc.subject.meshRetrospective Studiesen
dc.subject.meshRisk Assessmenten
dc.subject.meshRisk Factorsen
dc.subject.meshTumor Virus Infectionsen
dc.subject.meshUterine Cervical Dysplasiaen
dc.subject.meshUterine Cervical Neoplasmsen
dc.titleHPV genotypes in CIN 2-3 lesions and cervical cancer: a population-based study.en
dc.typeArticleen
dc.identifier.eissn1097-0215-
dc.contributor.departmentThe Icelandic Cancer Detection Clinic, Icelandic Cancer Society, Reykjavik, Iceland. kristjan@krabb.isen
dc.identifier.journalInternational journal of canceren

Related articles on PubMed

All Items in Hirsla are protected by copyright, with all rights reserved, unless otherwise indicated.